About The Medicines (NASDAQ:MDCO)
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.
Industry, Sector and Symbol
Industry Generic Pharmaceuticals
Trailing P/E Ratio-3.62404371584699
Forward P/E Ratio-3.74
Sales & Book Value
Annual Sales$167.84 million
Price / Sales14.40
Price / CashN/A
Book Value$9.21 per share
Price / Book3.60
Return on Equity-174.68%
Return on Assets-48.00%
The Medicines (NASDAQ:MDCO) Frequently Asked Questions
What is The Medicines' stock symbol?
The Medicines trades on the NASDAQ under the ticker symbol "MDCO."
How were The Medicines' earnings last quarter?
The Medicines Company (NASDAQ:MDCO) announced its earnings results on Wednesday, October, 25th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.95. The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $26.06 million. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The company's revenue was down 55.1% on a year-over-year basis. During the same period last year, the business posted ($0.64) EPS. View The Medicines' Earnings History.
When will The Medicines make its next earnings announcement?
Where is The Medicines' stock going? Where will The Medicines' stock price be in 2018?
9 Wall Street analysts have issued twelve-month price objectives for The Medicines' shares. Their forecasts range from $40.00 to $85.00. On average, they anticipate The Medicines' stock price to reach $53.67 in the next twelve months. View Analyst Ratings for The Medicines.
What are Wall Street analysts saying about The Medicines stock?
Here are some recent quotes from research analysts about The Medicines stock:
- 1. According to Zacks Investment Research, "The Medicines Co. has a blockbuster candidate, Inclisiran, in its pipeline. We also await a clearer picture of the commercial potential of Inclisiran, if approved. Moreover, The Medicines Co. has undertaken restructuring program to boost shareholder value. We are also encouraged by the company’s regular divesture of non-core products. This would help the company to optimize its capital structure and enhance its liquidity position. However, with Angiomax sales eroding due to presence of generics, the company’s ability to successfully develop and bring new products to the market is important for growth. Any regulatory setbacks would weigh heavily on the stock. The company’s shares have underperformed the industry in the last one year. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has negative record of earnings surprises in recent quarters." (2/6/2018)
- 2. Chardan Capital analysts commented, "We found particularly notable: (1) MDCO completing recruitment in just 11 weeks for its 1500-patient ORION-11 pivotal phase III trial of siRNA- based PSCK9 synthesis inhibitor inclisiran (partnered with Alnylam, Buy) and may thus have its first top-line pivotal results in 3Q19, (2) the confirmation commercial scale manufacturing for inclisiran has been achieved, and (3) new inclisiran efficacy data in HoFH to us suggesting efficacy beyond mAb PCSK9 inhibitors. With inclisiran to us having clear momentum towards 2H19E pivotal data and what we expect will be $4.7 billion in 2030E peak sales, we make MDCO a Chardan Top Pick for 2018." (1/24/2018)
- 3. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)
Who are some of The Medicines' key competitors?
Some companies that are related to The Medicines include FibroGen (FGEN), Anacor Pharmaceuticals (ANAC), Alere (ALR), VWR (VWR), Premier (PINC), Mediclinic International (MDC), AveXis (AVXS), ConvaTec Group (CTEC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Ansell (ANN), Array BioPharma (ARRY), Healthequity (HQY), GW Pharmaceuticals PLC- (GWPH), Ligand Pharmaceuticals (LGND), Mindray Medical International (MR), Shire Viropharma (VPHM) and Enerplus (ERF).
Who are The Medicines' key executives?
The Medicines' management team includes the folowing people:
- Fredric N. Eshelman Ph.D., Executive Chairman of the Board (Age 68)
- Clive A. Meanwell M.D. Ph.D., Chief Executive Officer, Director (Age 59)
- William Bernard O'Connor, Chief Financial Officer (Age 58)
- Christopher T. Cox, Executive Vice President, Chief Corporate Development Officer (Age 52)
- Jeffrey Frazier, Executive Vice President, Chief Human Strategy Officer (Age 54)
- Stephen M. Rodin J.D., General Counsel, Secretary (Age 41)
- Paris Panayiotopoulos, Director (Age 43)
- William W. Crouse, Independent Director (Age 74)
- Alexander J. Denner Ph.D., Independent Director (Age 47)
- Geno J. Germano, Independent Director (Age 56)
Who owns The Medicines stock?
The Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include Iridian Asset Management LLC CT (2.98%), Franklin Resources Inc. (2.82%), Sarissa Capital Management LP (2.64%), Slate Path Capital LP (2.37%), Alliancebernstein L.P. (1.75%) and Pinnacle Associates Ltd. (1.60%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Hiroaki Shigeta, Melvin K Spigelman, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines.
Who sold The Medicines stock? Who is selling The Medicines stock?
The Medicines' stock was sold by a variety of institutional investors in the last quarter, including Teachers Retirement System of The State of Kentucky, KBC Group NV, Pinnacle Associates Ltd., Creative Planning, Iguana Healthcare Management LLC, Alliancebernstein L.P., BlueCrest Capital Management Ltd and Metropolitan Life Insurance Co. NY. View Insider Buying and Selling for The Medicines.
Who bought The Medicines stock? Who is buying The Medicines stock?
The Medicines' stock was purchased by a variety of institutional investors in the last quarter, including Slate Path Capital LP, Carillon Tower Advisers Inc., Iridian Asset Management LLC CT, Broadfin Capital LLC, Millennium Management LLC, Sarissa Capital Management LP, Teachers Advisors LLC and University of Notre Dame DU Lac. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines.
How do I buy The Medicines stock?
Shares of The Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is The Medicines' stock price today?
One share of The Medicines stock can currently be purchased for approximately $33.16.
How big of a company is The Medicines?
The Medicines has a market capitalization of $2.42 billion and generates $167.84 million in revenue each year. The company earns $-119,110,000.00 in net income (profit) each year or ($9.15) on an earnings per share basis. The Medicines employs 410 workers across the globe.
How can I contact The Medicines?
The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY, NJ 07054, United States. The company can be reached via phone at +1-973-2906000 or via email at [email protected]
MarketBeat Community Rating for The Medicines (MDCO)MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
The Medicines (NASDAQ:MDCO) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||2.78||2.80|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$53.67||$55.25||$55.25||$53.22|
|Price Target Upside: ||76.13% upside||100.84% upside||70.58% upside||50.35% upside|
The Medicines (NASDAQ:MDCO) Consensus Price Target History
The Medicines (NASDAQ:MDCO) Analyst Ratings History
(Data available from 2/19/2016 forward)
The Medicines (NASDAQ:MDCO) Earnings History and Estimates Chart
The Medicines (NASDAQ MDCO) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/25/2017||Q3 2017||($1.37)||($0.42)||$26.06 million||$16.87 million||View||N/A|
|8/9/2017||Q2 2017||($1.29)||($5.52)||$29.64 million||$18.74 million||View||Listen|
|4/26/2017||Q1 2017||($1.13)||($1.44)||$37.76 million||$24.20 million||View||N/A|
|2/28/2017||Q416||($1.43)||($1.29)||$26.91 million||$25.20 million||View||Listen|
|10/26/2016||Q316||($1.38)||($0.64)||$37.26 million||$37.60 million||View||Listen|
|7/27/2016||Q216||($1.16)||($0.62)||$41.93 million||$54.70 million||View||Listen|
|5/9/2016||Q116||($0.89)||($1.03)||$48.96 million||$50.30 million||View||Listen|
|2/17/2016||Q415||($1.54)||($0.88)||$64.11 million||$67.20 million||View||N/A|
|11/3/2015||Q315||($0.88)||($0.90)||$68.58 million||$72.70 million||View||Listen|
|7/29/2015||Q215||($0.20)||($0.74)||$122.58 million||$90.50 million||View||Listen|
|5/5/2015||Q115||($0.68)||($0.02)||$138.78 million||$126.50 million||View||Listen|
|2/18/2015||Q414||($0.84)||$0.11||$188.55 million||$191.00 million||View||Listen|
|10/22/2014||Q314||($0.10)||$0.10||$188.30 million||$172.40 million||View||Listen|
|7/23/2014||Q214||($0.07)||$0.22||$183.75 million||$183.80 million||View||Listen|
|4/23/2014||Q114||($0.13)||$0.22||$175.60 million||$177.20 million||View||Listen|
|2/19/2014||Q413||$0.11||$0.26||$182.60 million||$185.00 million||View||Listen|
|10/23/2013||Q313||$0.24||$0.47||$173.86 million||$173.45 million||View||Listen|
|7/24/2013||Q2 2013||$0.33||$0.50||$168.70 million||$172.00 million||View||Listen|
|4/24/2013||Q1 2013||($0.26)||$0.31||$152.63 million||$155.80 million||View||Listen|
|2/20/2013||Q4 2012||$0.28||$0.38||$146.09 million||$159.50 million||View||Listen|
The Medicines (NASDAQ:MDCO) Earnings Estimates
2018 EPS Consensus Estimate: ($1.72)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for The Medicines (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by MarketBeat.com
The Medicines (NASDAQ MDCO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.22%
The Medicines (NASDAQ MDCO) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/15/2017||Clive Meanwell||CEO||Sell||136,250||$27.24||$3,711,450.00||587,652|| |
|12/8/2017||Fredric N Eshelman||Insider||Buy||200,000||$26.56||$5,312,000.00||1,028,383|| |
|11/29/2017||Alexander J Denner||Director||Buy||170,000||$30.03||$5,105,100.00||6,663|| |
|2/7/2017||William Bernard O'connor||CFO||Sell||25,833||$46.20||$1,193,484.60||30,935|| |
|12/8/2016||Christopher T Cox||EVP||Buy||105,500||$33.20||$3,502,600.00||33,670|| |
|12/8/2016||Fredric N Eshelman||Director||Buy||621,720||$33.77||$20,995,484.40||641,106|| |
|9/21/2016||Clive Meanwell||CEO||Sell||8,623||$40.00||$344,920.00||347,791|| |
|9/1/2016||Clive Meanwell||CEO||Sell||1,377||$40.00||$55,080.00||339,168|| |
|8/24/2016||Clive Meanwell||CEO||Sell||20,000||$40.00||$800,000.00||358,790|| |
|7/11/2016||Hiroaki Shigeta||Director||Sell||3,849||$38.50||$148,186.50||23,547|| |
|6/10/2016||Christopher T Cox||EVP||Buy||45,985||$37.90||$1,742,831.50||33,670|| |
|6/7/2016||Christopher T Cox||EVP||Buy||53,340||$37.55||$2,002,917.00||20,800|| |
|5/24/2016||Melvin K Spigelman||Director||Sell||15,000||$37.00||$555,000.00||53,970|| |
|5/16/2016||Clive Meanwell||CEO||Sell||10,000||$35.00||$350,000.00||348,790|| |
|5/16/2016||William Crouse||Director||Sell||15,000||$35.15||$527,250.00||53,970|| |
|5/13/2016||Elizabeth H S Wyatt||Director||Sell||15,000||$34.07||$511,050.00||49,817|| |
|5/12/2016||Fredric N Eshelman||Director||Buy||300,000||$33.68||$10,104,000.00||300,000|| |
|3/7/2016||Armin M Kessler||Director||Sell||8,100||$34.82||$282,042.00||144,930|| |
|11/13/2015||Robert G. Savage||Director||Sell||5,000||$39.34||$196,700.00||27,720|| |
|9/3/2015||Glenn Sblendorio||CFO||Sell||25,000||$42.00||$1,050,000.00||99,805|| |
|8/31/2015||Clive Meanwell||CEO||Sell||49,998||$39.36||$1,967,921.28||324,905|| |
|8/31/2015||Glenn Sblendorio||CFO||Sell||114,495||$39.75||$4,551,176.25||99,805|| |
|8/31/2015||Melvin K. Spigelman||Director||Sell||20,000||$40.50||$810,000.00||38,970|| |
|8/31/2015||William Bernard O'connor||SVP||Sell||35,451||$40.00||$1,418,040.00||24,732|| |
|7/1/2015||Clive Meanwell||CEO||Sell||16,667||$28.39||$473,176.13|| |
|6/25/2015||Glenn Sblendorio||CFO||Sell||3,305||$32.00||$105,760.00|| |
|6/8/2015||Hiroaki Shigeta||Director||Sell||7,500||$28.99||$217,425.00|| |
|5/20/2015||Robert G Savage||Director||Sell||15,000||$26.78||$401,700.00|| |
|4/16/2015||William Bernard O'connor||SVP||Sell||1,281||$30.00||$38,430.00|| |
|4/1/2015||Clive Meanwell||CEO||Sell||16,667||$27.58||$459,675.86|| |
|3/30/2015||Elizabeth H S Wyatt||Director||Sell||20,000||$28.08||$561,600.00|| |
|3/23/2015||Clive Meanwell||CEO||Sell||16,667||$30.62||$510,343.54|| |
|3/23/2015||Glenn Sblendorio||CFO||Sell||34,773||$30.78||$1,070,312.94|| |
|3/2/2015||William Bernard O'connor||SVP||Sell||2,988||$28.78||$85,994.64|| |
|3/3/2014||William Bernard O'connor||SVP||Sell||2,968||$30.31||$89,960.08||27,870|| |
|1/21/2014||Paul Michael Antinori||VP||Sell||37,883||$38.02||$1,440,311.66||31,029|| |
|1/15/2014||William Bernard O'connor||SVP||Sell||4,427||$39.15||$173,317.05||25,058|| |
|1/10/2014||William Bernard O'connor||SVP||Sell||72,384||$40.00||$2,895,360.00||25,058|| |
|1/7/2014||Clive Meanwell||CEO||Sell||27,929||$38.13||$1,064,932.77||297,773|| |
|1/3/2014||Clive Meanwell||CEO||Sell||57,516||$38.16||$2,194,810.56||297,773|| |
|12/9/2013||William Crouse||Director||Sell||12,500||$38.00||$475,000.00||29,849|| |
|12/5/2013||Glenn Sblendorio||CFO||Sell||8,516||$38.50||$327,866.00||118,405|| |
|12/2/2013||Clive Meanwell||CEO||Sell||10,000||$36.58||$365,800.00||307,773|| |
|11/26/2013||Clive Meanwell||CEO||Sell||135,000||$36.70||$4,954,500.00||317,773|| |
|10/23/2013||William Bernard O'connor||SVP||Sell||6,354||$35.00||$222,390.00|| |
|9/13/2013||Paul Michael Antinori||VP||Sell||73,500||$34.50||$2,535,750.00||51,906|| |
|9/3/2013||Clive Meanwell||CEO||Sell||7,500||$31.85||$238,875.00|| |
|8/1/2013||Clive Meanwell||CEO||Sell||7,500||$31.26||$234,450.00|| |
|7/8/2013||Paul Michael Antinori||VP||Sell||36,000||$33.00||$1,188,000.00|| |
|7/1/2013||Clive Meanwell||CEO||Sell||7,500||$31.25||$234,375.00|| |
|6/11/2013||Paul Michael Antinori||VP||Sell||109,973||$33.29||$3,661,001.17|| |
|5/29/2013||Armin M Kessler||Director||Sell||8,750||$33.05||$289,187.50|| |
|5/10/2013||Glenn Sblendorio||CFO||Sell||2,709||$37.00||$100,233.00|| |
|5/9/2013||Paul Michael Antinori||VP||Sell||35,000||$34.90||$1,221,500.00|| |
|5/9/2013||William Bernard O'connor||SVP||Sell||29,654||$35.00||$1,037,890.00|| |
The Medicines (NASDAQ MDCO) News Headlines
The Medicines (NASDAQ:MDCO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
The Medicines (NASDAQ:MDCO) Income Statement, Balance Sheet and Cash Flow Statement
The Medicines (NASDAQ MDCO) Stock Chart for Monday, February, 19, 2018